# US 2004/0082019 A1 · In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2004/0082019 A1
- Document ID: US20040082019A1
- Status: Published application
- Kind: A1
- Application number: 10/412,011
- Filed: 2003-04-11
- Published: 2004-04-29
- Earliest claimed: 2002-04-16
- Assignees: Hui Sunny Chang
- Inventors: Hui Sunny Chang; David Sack
- Web page: https://patentgrep.com/patent/US20040082019A1

## CPC

- G01N 33/5091: {for testing the pathological state of an organism}
- C07K 16/1239: {from Vibrionaceae (G)}
- G01N 33/6854: {Immunoglobulins}
- Y10S 530/861: involving IgG3, IgG4, IgA, or IgY
- Y10S 530/862: involving IgE or IgD
- Y10S 530/863: involving IgM
- Y10S 530/866: involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention provides methods of quantitating recent secreted antigen specific antibodies from supernatant of antibody secreting cells (ASC) in vitro culture for evaluation of vaccine or antigen induced antigen specific antibody secretion without ex vivo antigen stimulation.

## Claims

### Claim 1

A method for detecting the level or the presence of secreting antibodies in a subject, said method comprising the steps of (i) obtaining a sample comprising the supernatant of the ex vivo culture of the said subject's antibody secreting cells (ASC), and lacking of serum antibodies, and without any ex vivo said antigen stimulation to the ASC culture or to the ex vivo material where the said ASC cells resides, and (ii) determining the level or the presence of said secreting antibodies in said sample using an immunoassay.

### Claim 2 (depends on 1)

The method of claim 1, wherein said antibody secreting cells (ASC) is peripheral blood mononuclear cells (PBMC) which containing antibody secreting cells and lacking of serum antibodies.

### Claim 3 (depends on 1)

The method of claim 1, wherein said secreting antibodies are in the form in whole or in part of the said antibody's structure.

### Claim 4 (depends on 1)

The method of claim 1, wherein said subject is a human or a mammalian animal or any subject with a immune system which can be in vivo immune stimulated with said antigen and can produce at least one ex vitro cultivable antibody secreting cell.

### Claim 5 (depends on 1)

The method of claim 1, wherein said antigen is derived from a pathogen.

### Claim 6 (depends on 1)

The method of claim 1, wherein said antigen is a vaccine.

### Claim 7 (depends on 1)

The method of claim 1, wherein said antigen is derived from an antigenic substance, which can induce an antibody immune response in the said subject.

### Claim 8 (depends on 1)

The method of claim 1, wherein said subject was previously immunized with a vaccine comprising said antigen.

### Claim 9 (depends on 1)

The method of claim 1, wherein said subject was previously infected with a pathogen from which said antigen was derived.

### Claim 10 (depends on 1)

The method of claim 1, wherein said subject was previously in vivo stimulated with said antigenic substance via immunological route(s).

### Claim 11 (depends on 1)

The method of claim 1, wherein said immunoassay is an enzyme-linked immunosorbent assay.

### Claim 12 (depends on 1)

The method of claim 1, wherein said immunoassay is an assay quantifies or determines the presence of antibodies.

### Claim 13 (depends on 1)

The method of claim 1, wherein said antibodies are said antigen specific antibodies.

### Claim 14 (depends on 1)

The method of claim 1, wherein said antibodies are antibodies of the said subject.
